癌细胞中不正常的lncRNA表达可能会影响它们的关键表型。我们旨在总结有关lncRNA TPT1-AS1在癌症中的临床病理学和预后价值的现有证据。使用涵盖 lncRNA TPT1-AS1、癌症和临床结果的相关关键词在 Medline 和 Embase 数据库上进行了系统搜索。使用随机效应模型汇总了效应量估计及其 95% 置信区间 (CI)。采用STATA 16.0软件进行元分析。满足我们资格标准的文章共17篇。肿瘤组织相比正常组织表现出lncRNA TPT1-AS1表达水平增加（汇总标准化平均差异(95% CI)：0.65(0.52-0.79)）。这种lncRNA的过度表达是预后不良的重要预测因子（汇总对数秩检验P值<0.001）；在具有高水平lncRNA TPT1-AS1的患者中，五年死亡风险比其对照组增加了1.40倍。lncRNA TPT1-AS1与肿瘤分期、肿瘤大小和淋巴结转移的相关性汇总奥斯比比率分别为1.94(95% CI:0.90-4.19,8项研究，I2=79.6%)，2.33(95% CI:1.31-4.14,5项研究，I2=40.0%)和1.89(95%CI：1.08-3.36，5项研究，I2=61.7%)。关于已确定的潜在机制，lncRNA TPT1-AS1主要通过吸附miRNA并调节其下游靶向基因或控制关键细胞周期调节因子的表达来发挥对癌细胞生长的作用。在癌症患者中，lncRNA TPT1-AS1的表达升高可能与生存率缩短、晚期分期、更大肿瘤大小和淋巴结转移相关。版权所有©2023 Elsevier GmbH。保留所有权利。

Aberrant expression of lncRNAs in cancer cells can impact their key phenotypes. We aimed to summarize available evidence on clinicopathological and prognostic value of lncRNA TPT1-AS1 in cancer.A systematic search was performed on Medline and Embase databases using relevant key terms covering lncRNA TPT1-AS1, cancer, and clinical outcomes. The effect size estimates and their 95 % confidence interval (CI) were pooled using random-effects models. Meta- analyses were conducted using STATA 16.0 software.Seventeen articles met our eligibility criteria. Tumor tissue compared to normal tissue showed increased level of lncRNA TPT1-AS1 expression (pooled standardized mean difference (95 % CI): 0.65 (0.52-0.79)). Overexpression of this lncRNA was a significant predictor for poor prognosis (Pooled log-rank test P-value < 0.001); in patients with high-level of lncRNA TPT1-AS1, the risk of death at five years was 1.40 times greater than their counterparts. The pooled Odds ratios for association lncRNA TPT1-AS1 with tumor stage, tumor size, and lymph node metastasis were 1.94 (95 % CI: 0.90-4.19, 8 studies, I2 = 79.6 %), 2.33 (95 % CI: 1.31-4.14, 5 studies, I2 = 40.0 %), and 1.89 (95 % CI: 1.08-3.36, 5 studies, I2 = 61.7 %), respectively. Regarding the identified potential mechanisms, lncRNA TPT1-AS1 plays a role in cancer growth mainly by sponging miRNAs and regulating their downstream targets or controlling the expression of key cell cycle regulators.In cancer patients, elevated expression of lncRNA TPT1-AS1 might be associated with a shorter Overall Survival, advanced stages, larger tumor size, and lymph node metastasis.Copyright © 2023 Elsevier GmbH. All rights reserved.